OBJECTIVE: Despite available support, sexuality needs are the most frequently reported unmet need among men with prostate cancer, which may be due to low help-seeking rates. Using the Ecological Systems Framework as a theoretical foundation, we conducted a scoping review of the available literature to understand what factors impact help-seeking behaviour for sexual issues after prostate cancer treatment among men who had received treatment.
METHODS: Following PRISMA guidelines, a systematic search on Medline, PsychInfo, Embase, Emcare, and Scopus was conducted to identify studies of adult prostate cancer patients post-treatment, which reported barriers and/or facilitators to help-seeking for sexual health issues. Quality appraisals were conducted using Joanna Briggs Institute appraisal tools, and results were qualitatively synthesised.
RESULTS: Of the 3870 unique results, only 30 studies met inclusion criteria. In general, studies were considered moderate to good quality, though only six used standardised measures to assess help-seeking behaviour. Barriers and facilitators for sexual help-seeking were identified across all five levels of the Ecological Systems Framework, including age, treatment type, and previous help seeking experience (individual level), healthcare professional communication and partner support (microsystem), financial cost and accessibility of support (meso/exosystem), and finally embarrassment, masculinity, cultural norms, and sexuality minority (macrosystem).
CONCLUSIONS: Addressing commonly reported barriers (and inversely, enhancing facilitators) to help-seeking for sexual issues is essential to ensure patients are appropriately supported. Based on our results, we recommend healthcare professionals include sexual wellbeing discussions as standard care for all prostate cancer patients, regardless of treatment received, age, sexual orientation, and partnership status/involvement.

The fact of having suffered Childhood Sexual Abuse (ASI) is considered a risk factor for the subsequent development of sexual dysfunctions, these being more frequent among women than among men. The objective of this work is to analyze the different sexual dysfunctions in people who have suffered ASI, with addiction problems and in the general population. The sample is made up of 426 participants (241 men and 185 women). A retrospective ex post facto study has been carried out using a sociodemographic data questionnaire (ad hoc) and the Golombok Rust Inventory of Sexual Satisfaction (GRISS). For data analysis, the Kolomogorov-Smirnov and Mann Whitney U tests were performed. The Mann-Whitney U test has been carried out to verify if there are significant differences between the people who present sexual dysfunction, between the groups that have suffered sexual abuse and have addiction problems, and the group that has not suffered sexual abuse and have addiction problems. The results indicate that the variables in which significant differences are found are the following: Dissatisfaction (p = 0.013), Avoidance (p < 0.001), No sensuality (p = 0.008), Vaginismus (p < 0.001), Anorgasmia (p < 0.001), erectile dysfunction (p = 0.045), and premature ejaculation (p = 0.007). The average scores that have been obtained among people who have addiction problems, without having suffered ASI in comparison with those who have suffered it, are the following: Dissatisfaction (5.09 vs. 6.41), Avoidance (2.03 vs. 2.22), No Sensuality (2.96 vs. 4.50), Vaginismus (0.88 vs. 2.94), Anorgasmia (0.97 vs. 3.78), Erectile Dysfunction (2.41 vs. 1.69), Premature Ejaculation (3.60 vs. 2.22). People who have suffered ASI present, with a greater probability, sexual dysfunctions than those who have not suffered it.

BACKGROUND: Since the brutal October 7, 2023 attacks on Israel, the encroachment of the battlefield into the daily lives of all Israelis has impacted both civilians and combatants in various ways. The development of post-traumatic stress reactions has far-reaching effects across numerous aspects of life. One of the lesser-discussed consequences is the onset of sexual dysfunction. Reactions to such distressing events can adversely affect sexual desire, arousal, orgasm, the frequency of sexual activities, and satisfaction derived from them. These issues may present directly in clinical settings, or indirectly through other symptoms. The impact of trauma on sexual function can be attributed to disruptions in biological mechanisms, cognitive impairments, mood changes, and diminished motivation. This review explores how responses to post-traumatic stress relate to sexual function. We present case studies of patients recovering from such events, describe the underlying mechanisms that trigger these adverse reactions, and discuss interventions that can enhance sexual health, which can be implemented in primary care settings. It is advisable for assessments of sexual function to be included in routine evaluations by primary care physicians. Early identification of sexual dysfunction can help prevent the progression of more persistent issues and enhance overall quality of life for patients.

暂无摘要。

暂无摘要。

暂无摘要。

BACKGROUND: Sexual dysfunction is the most frequent health problem among psychiatric patients. This could be the result of both the nature of the illness itself and the side effects of prescribed psychotropic medications. It also significantly affects an individual\'s general well-being, interpersonal relationships, self-esteem, and treatment outcomes. Therefore, the current systematic review and meta-analysis was conducted to determine the combined prevalence of sexual dysfunction and its correlated factors among people with mental illness.
METHODS: We retrieved eligible primary studies using various search databases like PubMed, EMBASE, Science Direct, African Journal Online, Google Scholar, and Psychiatry Online. The report of this systematic review was reported following the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. We used standardized data extraction checklists and STATA version 14 for data extraction and analysis, respectively. The I-squared statistics test was used to check statistical heterogeneity within the included articles. Publication bias was assessed using a funnel plot and the Egger test. To estimate the overall prevalence and correlated factors of sexual dysfunction, a random effects model meta-analysis was employed.
RESULTS: In this meta-analysis, a total of 15 primary studies with 2849 psychiatric patients were included. The overall pooled prevalence of sexual dysfunction among psychiatric patients in Africa was 58.42% (95% CI: 49.55, 67.28). Having older age (OR = 1.92, 95% CI: 1.28, 2.87), longer duration of illness (OR = 2.60, 95% CI: 1.14, 5.93), history of relapse (OR = 3.51, 95% CI: 1.47, 8.43), poor quality of life (OR = 3.89, 95% CI: 2.15, 7.05), and antipsychotic medications (OR = 2.99, 95% CI: 1.84, 4.86) were significantly associated with sexual dysfunction.
CONCLUSIONS: This meta-analysis revealed that approximately two-thirds of psychiatric patients in Africa are affected by sexual dysfunction. Therefore, the findings of this study recommend that when evaluating psychiatric patients, health professionals should focus more on sexual dysfunction. It is also essential to promote awareness and incorporate sexual health assessment and intervention into mental health services to reduce the overall burden of the problem.

The endocrine system intricately regulates male sexual development and health which influences masculinization, sexual libido, muscle mass, bone density, and overall vitality. Disorders in the hypothalamic-pituitary-gonadal axis can lead to hypogonadism, gynecomastia, sexual dysfunction, and infertility. Testosterone replacement therapy can be considered for symptomatic hypogonadism but poses risks for azoospermia and polycythemia, along with uncertain impact on cardiovascular disease. Gynecomastia results from a high estrogen-to-androgen ratio, mostly from either excess estrogen or decreased androgens. Sexual dysfunction is more commonly secondary to psychological or metabolic disorders; consider workups to rule out endocrine etiologies including hypogonadism if indicated.

BACKGROUND: Sexual health is a critical component of overall well-being, yet discussions around sexual function, especially in the context of postpartum recovery, are often taboo or sidelined. The aim was to review measurement tools assessing women\'s sexual function/health during the postpartum period.
METHODS: We did a systematic search according to preferred reporting items for systematic reviews and meta-analyses 2020 guidelines in different databases, including PubMed, Web of Science, Scopus, Embase, ProQuest and Open Access Thesis and Dissertations, and Google scholar search engine until June 2023. Also, the reference list of the related reviews has been screened. Eligible studies included observational studies or clinical trials that evaluated women`s sexual function during the postpartum period using existing tools. Data extraction covered study characteristics, measurement tools, and their validity and reliability.
RESULTS: From 3064 retrieved records, after removing duplicates and excluding ineligible studies, and reviewing the reference list of the related reviews, 41 studies were included in this review. Tools measuring sexual function were developed from 1996 to 2017. Sexual activity questionnaire, female sexual function index (FSFI), sexual function questionnaire, short form of the pelvic organ prolapse/urinary incontinence sexual questionnaire, sexual health outcomes in women questionnaire, shorter version of FSFI, and sexual function questionnaire\'s medical impact scale and Carol scale.
CONCLUSIONS: Sexual activity questionnaire, FSFI, sexual function questionnaire, short form of the pelvic organ prolapse/urinary incontinence sexual questionnaire, sexual health outcomes in women questionnaire, shorter version of FSFI, sexual function questionnaire\'s medical impact scale, and Carol scale are valid and reliable measuring tools to assess sexual function or sexual health during postpartum period, which can be used in primary studies according to the study aim and objectives.

Objectives: To report the sexual functional outcomes of vaginal dilation therapy in Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome patients. Methods: From March 2020 to February 2023, 97 MRKH syndrome patients performed vaginal dilation therapy with guidance from Peking Union Medical College Hospital, and 45 of them engaged in penetrative intercourse and were included in this prospective cohort study. The Chinese version of female sexual function index (FSFI) was used to assess sexual function. Functional success was defined as FSFI>23.45. Forty age-matched healthy women were selected as controls. Kaplan-Meier survival analysis was used to calculate the median time to success. Pearson correlation analysis was used to explore the relationship between neovagina length and sexual function. Complications were collected using follow-up questionnaires. Results: The functional success rate of vaginal dilation therapy was 89% (40/45) with a median time to success of 4.3 months (95%CI: 3.0-6.1 months). Compared to controls, MRKH syndrome patients had significantly lower scores in the orgasm domain (4.72±1.01 vs 4.09±1.20; P=0.013) and pain domain (5.03±0.96 vs 4.26±0.83; P<0.001). However, there were no significant differences in the FSFI total score (26.77±2.70 vs 26.70±2.33; P=0.912), arousal domain (4.43±0.77 vs 4.56±0.63; P=0.422) and satisfaction domain (4.88±0.98 vs 4.65±0.86; P=0.269) between MRKH syndrome patients and controls. MRKH syndrome patients had significantly higher scores in the desire domain (3.33±0.85 vs 3.95±0.73; P<0.001) and lubrication domain (4.37±0.56 vs 5.20±0.67; P<0.001). The prevalence of sexual dysfunction in MRKH patients was non-inferior to controls: low desire [3% (1/40) vs 23% (9/40); P=0.007], arousal disorder [3% (1/40) vs 3% (1/40); P>0.999], lubrication disorder [5% (2/40) vs 25% (10/40); P=0.012], orgasm disorder [40% (16/40) vs 20% (8/40); P=0.051], sexual pain [30% (12/40) vs 15% (6/40); P=0.108]. Conclusions: MRKH syndrome patients undergoing non-invasive vaginal dilation therapy could achieve satisfactory sexual life. Given its high functional success rate and slight complication, vaginal dilation therapy should be recommended as the first-line option, reducing the need for unnecessary surgeries.
目的： 评估顶压法人工阴道成形术的Mayer-Rokitansky-Küster-Hauser（MRKH）综合征患者的性功能、功能学成功率及并发症。 方法： 本研究为前瞻性队列研究，选取2020年3月至2023年2月于北京协和医院行顶压法人工阴道成形术的MRKH综合征患者共97例，其中45例顶压治疗开始后有阴茎插入式性生活被纳入本研究（即观察组）。采用经中文验证的女性性功能指数量表（FSFI）对患者性功能进行评估，采用FSFI总分>23.45分为功能学成功标准；同时选择40例年龄匹配的正常妇女作为对照组。采用Kaplan-Meier法计算顶压开始至成功所需的时长。采用Pearson相关性分析计算阴道长度与FSFI评分之间的关系。通过随访问卷记录患者顶压过程中出现的并发症。 结果： 89%（40/45）的观察组MRKH综合征患者顶压后达到功能学成功标准，成功所需的中位时长为4.3个月（95%CI为3.0~6.1个月）。与对照组相比，虽然观察组的性高潮评分［分别为（4.72±1.01）、（4.09±1.20）分；P=0.013］和疼痛程度评分［分别为（5.03±0.96）、（4.26±0.83）分；P<0.001］低于对照组，但观察组在FSFI总分［（26.77±2.70）、（26.70±2.33）分；P=0.912］、性欲望评分［（3.33±0.85）、（3.95±0.73）分；P<0.001］、性唤起评分［（4.43±0.77）、（4.56±0.63）分；P=0.422］、阴道润滑程度评分［（4.37±0.56）、（5.20±0.67）分；P<0.001］和满意度评分［（4.88±0.98）、（4.65±0.86）分；P=0.269］方面均不劣于对照组。功能学成功的观察组患者各项性功能障碍的发生率与对照组比较显示，性欲低下［分别为3%（1/40）、23%（9/40）；P=0.007］和阴道润滑障碍［分别为5%（2/40）、25%（10/40）；P=0.012］的发生率显著低于对照组，而性唤起障碍［均为3%（1/40）；P>0.999］、性高潮障碍［分别为40%（16/40）、20%（8/40）；P=0.051］、性交痛［分别为30%（12/40）、15%（6/40）；P=0.108］的发生率无显著差异。顶压过程中出现的并发症主要包括轻中度阴道疼痛（67%，30/45）、阴道点滴出血（33%，15/45）和尿路刺激征（9%，4/45）。 结论： 无创的顶压法人工阴道成形术成功率高，并发症轻微，患者性生活满意度高。应当推广顶压法作为MRKH综合征患者阴道重建的一线治疗方案，减少不必要的手术。.